Celltrion News - Latest Updates & Headlines
Celltrion gets interchangeability approval for biosimilar of Humira in US
Seoul, April 14: Celltrion, a major South Korean biopharmaceutical firm, on Monday said it has obtained an interchangeability approval for its biosimilar drug for autoimmune disease treatment in the United States.
Celltrion targets $3.46 bn in sales this year on biosimilars
Seoul, March 18: Celltrion, a major South Korean biopharmaceutical firm, on Tuesday said it aims to achieve 5 trillion won ($3.46 billion) in sales this year, helped by an expanded biosimilar lineup.
Celltrion launches autoimmune disease treatment in US
Seoul, March 13: Celltrion, a major South Korean biopharmaceutical firm, on Thursday said it has launched its biosimilar product for Stelara, an autoimmune disease treatment, in the United States.
S.Korean drugmaker Celltrion gets USFDA approval for allergic asthma biosimilar
Seoul, March 10: Celltrion, a major South Korean biopharmaceutical firm, said on Monday that its biosimilar for asthma and other chronic allergic diseases has obtained approval for sales in the US market.
Celltrion's bone disease biosimilars get approval in US
Seoul, March 4: Celltrion, a major South Korean biopharmaceutical firm, said on Tuesday its two new bio-similars for bone disease treatment have obtained approval from the United States.
Celltrion's autoimmune disease treatment gets approval in Europe
Seoul, Feb 24: Celltrion, a major South Korean biopharmaceutical firm, on Monday said its new biosimilar for an autoimmune disease treatment has obtained approval from the European Commission (EC).
Celltrion gets US FDA approval for new biosimilar for autoimmune disease treatment
Seoul, Jan 31: Celltrion, a major South Korean biopharmaceutical firm, on Friday said its new biosimilar for an autoimmune disease treatment has received approval from the US Food and Drug Administration (FDA).
Celltrion's autoimmune disease treatment hits 5 major European countries
Seoul, Jan 23: South Korean drug major Celltrion's autoimmune disease treatment has been launched in five major European nations, the company said on Thursday.